


Meningococcal Vaccines for Adolescents & Young Adults: Routine Risk¹




Routine MenACWY^{2,3} for 11-18 years

2 Doses




Shared Clinical Decision-Making MenB² for 16-23 years (16-18 preferred)

2 Doses



Pentavalent Vaccine (MenABCWY)² Suggested Dosing for 11-23 years

3 Doses



1. For **high-risk populations** (increased exposure to meningococcal disease, HIV infection, complement deficiencies or asplenia), ([EZIZ.org/assets/docs/IMM-1218.pdf](#)) ([cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html](#))
2. MenACWY and MenB vaccines each protect against different serogroups. They may be given at the same visit. If a patient is receiving MenACWY and MenB vaccines at the same visit, **MenABCWY** may be given instead.
3. MenACWY (MCV4) vaccines protect against serogroups A, C, W-135, and Y.
4. One dose of MenACWY is also recommended for previously unvaccinated or incompletely vaccinated first-year college students living in residence halls and military recruits and may be administered to persons aged 19-21 yrs. who have not received a dose after their 16th birthday.
5. A two-dose series is recommended for persons who are not at increased risk for meningococcal disease. A three-dose (0, 1-2, and 6 months) series is recommended for **persons at increased risk, including during outbreaks of serogroup B disease** ([EZIZ.org/assets/docs/IMM-1218.pdf](#)).
6. Subsequent MenB dose(s) after Penbraya (which contains Trumenba) or Penmenvy (which contains Bexsero) must be Trumenba or Bexsero, respectively, since MenB brands are not interchangeable.